Form 4 NeuroPace Inc For: Nov 29 Filed by: KCK LTD.

Neuropace, Inc. (NPCE)
Company Research
Source: SEC EDGAR

Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th [Yahoo! Finance]Yahoo! Finance
- NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9thGlobeNewswire
- NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Wells Fargo & Company from $13.00 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- NeuroPace Issues 2025 Financial Guidance TargetsGlobeNewswire
- NeuroPace, Inc. (NASDAQ: NPCE) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
NPCE
Earnings
- 11/12/24 - Beat
NPCE
Sec Filings
- 2/4/25 - Form SCHEDULE
- 1/31/25 - Form 4
- 1/30/25 - Form 144
- NPCE's page on the SEC website